Early Disease Progression after Intravesical Bacillus Calmette-Guérin (BCG) Therapy for Superficial Bladder Cancer

International Journal of Urology

Volumn 3, Issue 1, 1996, Pages 18-22

  Kanamaru, Hiroshi ^a   Saikawa, Shigeki ^a   Muranaka, Koji ^a   Mori, Hirotaka ^a   Akino, Hironobu ^a   Miwa, Yoshiji ^b   Nakamura, Naohiro ^c   Fujita, Tomohiro ^d   Okada, Kenichiro ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b Obama Municipal Hospital   (Japan)

^c Nagahama City Hospital   (Japan)

^d Nakamura Hospital   (Japan)

Author keywords

Bacillus Calmette Guerin; BCG; Bladder cancer; Progression

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER INVASION; CANCER MORTALITY; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL FEATURE; CYSTECTOMY; CYSTOSCOPY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MALE; METASTASIS; MUSCLE; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE; RISK FACTOR; TREATMENT FAILURE; URINE CYTOLOGY;

ADULT; AGED; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URETER; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 0029882044     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1996.tb00623.x     Document Type: Article

References (12)

1. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD and Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with Bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 1991;325:1205-1209.
2. Sarosdy MF, Lamm DL. Long-term results of intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 1989;142:719-722.
3. Herr HW, Wartinger DD, Fair WR and Oettgen HF. Bacillus Calmette-Guérin therapy for superficial bladder cancer: A 10-year follow-up. J Urol 1992;147: 1020-1023.
4. Kamat MR, Hulkarni JN, Tongaonkar HB, Dalal AV. Intravesical Bacillus Calmette-Guérin for superficial bladder cancer: Experience with Danish 1331 Strain. J Urol 1994;152:1424-1428.
5. Nadler RB, Catalona WJ, Hudson MA and Ratliff TL. Durability of the tumor - free response for intravesical Bacillus Calmette-Guérin therapy. J Urol 1994;152: 367-373.
6. Nishibuchi S, Nakamura N, Kanimoto Y and Okada K. Intravesical Bacillus Calmette-Guérin instillation therapy for carcinoma in situ of the urinary bladder. Nishinihon J Urol 1992;54:1012-1016.
7. Saikawa S, Nishibuchi S, Akino H, Wada O, Miwa Y and Okada K. Rapid progression of bladder cancer from complete remission following Bacillus Calmette-Guérin instillation therapy: A report of three cases. Nishinihon J Urol 1995;57:260-263.
8. General Rule for Clinical and Pathological Studies on Bladder Cancer, 2nd ed. Japanese Urological Association, The Japanese Society of Pathology, Tokyo, Kanehara, 1992.
9. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 1987;137:220-224.
10. Klein EA, Rogatko A, Herr HW. Management of local Bacillus Calmette-Guérin failures in superficial bladder cancer. J Urol 1992;147:601-605.
11. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with Bacillus Calmette-Guérin: A multivariate analysis of factors affecting tumor progression. J Urol 1989;141:22-29.
12. Schellhammer PF, Ladaga LE, Moriarty RP. Intravesical Bacillus Calmette-Guérin for treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder. J Urol 1994;153:53-56.